Case Discussion: Systemic Therapy for Metastatic Renal Cell Carcinoma

Area of Science:

• Oncology
• Medical Therapeutics

Background:

• Metastatic renal cell carcinoma (mRCC) presents significant treatment challenges.
• Effective first-line systemic therapies are crucial for improving patient outcomes.

Purpose of the Study:

• To outline the recommended first-line systemic therapy for metastatic renal cell carcinoma.
• To identify appropriate targeted agents based on clinical factors.

Main Methods:

• Review of current clinical guidelines and evidence for mRCC treatment.
• Analysis of targeted agents, including VEGF- and mTOR-directed therapies.

Main Results:

• Targeted agents are the cornerstone of first-line treatment for mRCC.
• Selection of specific agents (VEGF- or mTOR-directed) depends on individual patient clinical characteristics.

Conclusions:

• First-line systemic therapy for mRCC should prioritize targeted agents.
• Personalized treatment selection, considering VEGF or mTOR pathways, is essential.